Evidence map›Paper›PMID 37801085›Full record

ReviewAnnals of hematology2024

Can novel methods replace the gold standard chimerism method after allogeneic hematopoietic stem cell transplantation?

Figen Abatay Sel, Fatma Savran Oğuz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Figen Abatay SelDepartment of Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. figen.abatay@gmail.com.ORCID http://orcid.org/0000-0002-1155-1284
Fatma Savran OğuzDepartment of Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-6018-8936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After hematopoietic stem cell transplantation, chimerism assay is a useful approach to monitor the success of the transplant and to select the appropriate treatment strategy, such as donor leukocyte infusion or immunosuppressive drug dosage. Short tandem repeat PCR is the method that has been accepted as the gold standard for chimerism. However, it has not yet been sufficient to detect mixed chimerism in patients with minimal residual disease. Simultaneously, recent years have been marked by developing sensitive, high-throughput, and accurate molecular genetic assays. These novel methods have subsequently been adapted for the analysis of post-transplant chimerism. In this review, we discuss the technical features of both novel and conventional gold standard chimerism assays. We also discuss their advantages and disadvantages.

Indexed as

ChimerismHematopoietic Stem Cell TransplantationHumansMicrosatellite RepeatsNeoplasm Recurrence, LocalTransplantation ChimeraTransplantation, HomologousChimerism monitoringDd-PCRMolecular diagnosticsMultiplex STR-PCRNGSqPCR

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.